Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 6,205,700 | 4,162,800 | 3,047,597 | 2,488,652 | 1,702,177 |
| Cost of Goods | 736,300 | 547,800 | 409,539 | 275,119 | 210,460 |
| Gross Profit | 5,469,400 | 3,615,000 | 2,638,058 | 2,213,533 | 1,491,717 |
| Operating Expenses | 2,613,400 | 2,418,300 | 2,003,447 | 2,090,409 | 1,482,241 |
| Operating Income | 2,856,300 | 1,197,500 | 635,150 | 123,243 | 9,936 |
| Interest Expense | 58,200 | 58,500 | 72,471 | 69,298 | 81,432 |
| Other Income | 318,800 | 255,900 | 37,562 | -69,634 | 4,130 |
| Pre-tax Income | 3,116,900 | 1,394,900 | 600,241 | -15,689 | -67,366 |
| Income Tax | 405,200 | 218,100 | -1,486,862 | -107,324 | 16,665 |
| Net Income Continuous | 2,711,700 | 1,176,800 | 2,087,103 | 91,635 | -84,031 |
| Minority Interests | N/A | N/A | -9,793 | -171,849 | 28,021 |
| Net Income | $2,711,700 | $1,176,800 | $2,096,896 | $263,484 | $-112,052 |
| EPS Basic Total Ops | 10.44 | 4.58 | 8.24 | 1.06 | -0.46 |
| EPS Basic Continuous Ops | 10.44 | 4.58 | 8.21 | 0.37 | -0.34 |
| EPS Diluted Total Ops | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 |
| EPS Diluted Continuous Ops | 10.30 | 4.51 | 8.05 | 0.36 | -0.34 |
| EPS Diluted Before Non-Recurring Items | 9.03 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $2,965,800 | $1,304,400 | $707,570 | $184,640 | $71,334 |